Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine’s Antidepressant Effect—Reply

2019 ◽  
Vol 76 (6) ◽  
pp. 658 ◽  
Author(s):  
John H. Krystal ◽  
Gihyun Yoon ◽  
Ismene L. Petrakis
2019 ◽  
Vol 76 (6) ◽  
pp. 657 ◽  
Author(s):  
Boris D. Heifets ◽  
Nolan R. Williams ◽  
Brandon S. Bentzley ◽  
Alan F. Schatzberg

2002 ◽  
Vol 72 (1-2) ◽  
pp. 93-99 ◽  
Author(s):  
Srinivas Gullapalli ◽  
Kumar V.S. Nemmani ◽  
Poduri Ramarao

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Stefanie Corradini ◽  
Maximilian Niyazi ◽  
Dirk Verellen ◽  
Vincenzo Valentini ◽  
Seán Walsh ◽  
...  

AbstractFuture radiation oncology encompasses a broad spectrum of topics ranging from modern clinical trial design to treatment and imaging technology and biology. In more detail, the application of hybrid MRI devices in modern image-guided radiotherapy; the emerging field of radiomics; the role of molecular imaging using positron emission tomography and its integration into clinical routine; radiation biology with its future perspectives, the role of molecular signatures in prognostic modelling; as well as special treatment modalities such as brachytherapy or proton beam therapy are areas of rapid development. More clinically, radiation oncology will certainly find an important role in the management of oligometastasis. The treatment spectrum will also be widened by the rational integration of modern systemic targeted or immune therapies into multimodal treatment strategies. All these developments will require a concise rethinking of clinical trial design. This article reviews the current status and the potential developments in the field of radiation oncology as discussed by a panel of European and international experts sharing their vision during the “X-Change” symposium, held in July 2019 in Munich (Germany).


2019 ◽  
Vol 122 (1) ◽  
pp. 1-3 ◽  
Author(s):  
Adrian L. Harris

AbstractCancer metabolism has undergone a resurgence in the last decade, 70 years after Warburg described aerobic glycolysis as a feature of cancer cells. A wide range of techniques have elucidated the complexity and heterogeneity in preclinical models and clinical studies. What emerges are the large differences between tissues, tumour types and intratumour heterogeneity. However, synergies with inhibition of metabolic pathways have been found for many drugs and therapeutic approaches, and a critical role of window studies and translational trial design is key to success.


2017 ◽  
Vol 152 (5) ◽  
pp. S212
Author(s):  
Muriel H. Larauche ◽  
Nabila Moussaoui ◽  
Mandy Biraud ◽  
Won Ki Bae ◽  
Wendy Walwyn ◽  
...  

2015 ◽  
Vol 35 (35) ◽  
pp. 12217-12231 ◽  
Author(s):  
L. Hipolito ◽  
A. Wilson-Poe ◽  
Y. Campos-Jurado ◽  
E. Zhong ◽  
J. Gonzalez-Romero ◽  
...  

2006 ◽  
Vol 85 (3) ◽  
pp. 545-554 ◽  
Author(s):  
S PRIMEAUX ◽  
S WILSON ◽  
A MCDONALD ◽  
F MASCAGNI ◽  
M WILSON

Sign in / Sign up

Export Citation Format

Share Document